Corgentech Announces Management Promotions
January 19 2006 - 7:00AM
PR Newswire (US)
SOUTH SAN FRANCISCO, Calif., Jan. 19 /PRNewswire-FirstCall/ --
Corgentech Inc. (NASDAQ:CGTK) today announced the election of four
individuals to vice president-level positions. The appointments
include the promotions of Rolf O. Ehrhardt, M.D., Ph.D. to vice
president, preclinical development; Melissa Morandi to vice
president, quality assurance; Patricia Richards, M.D., Ph.D. to
vice president, clinical research; and Jennifer Cook Williams to
vice president, investor relations. "As we integrate our newly
merged company and prepare for commercialization and further
late-stage clinical development, it is key that we have the right
team in place to achieve our goals, one of which includes filing a
new drug application this year for our lead product candidate,
ALGRX 3268," stated John P. McLaughlin, chief executive officer of
Corgentech. "We have an executive team with a depth of experience
in many critical areas including marketing and commercialization,
clinical development and regulatory affairs and believe that Dr.
Ehrhardt, Ms. Morandi, Dr. Richards and Ms. Williams will provide
even further strength to our leadership team." Rolf O. Ehrhardt,
M.D. Ph.D., vice president of preclinical development, joined
Corgentech in 2003 and most recently served as senior director,
Inflammation in the research department. Dr. Ehrhardt has over 15
years of experience in drug development and translational science.
Prior to joining Corgentech, he was the founding president of
BioSeek, Inc., where he raised nearly $20 million in private
financing rounds. Before that, Dr. Ehrhardt was at Protein Design
Labs (now PDL BioPharma), where he led a scientific group focused
on new target discovery/validation and development of
immunotherapeutics. Prior to that, he was a Deutsche
Forschungsgemeinschaft (DFG: German Research Foundation) and
Fogarty fellow at the National Institutes of Health where his focus
was on mucosal immunology and inflammatory bowel disease. He
obtained his M.D. and Ph.D. with distinction from the Technical
University of Munich, Germany. Melissa Morandi, vice president of
quality assurance, joined Corgentech in 2004 and most recently
served as senior director of quality assurance drug and device.
Prior to joining Corgentech, Ms. Morandi held director positions in
Quality Assurance and Compliance at Biogen Idec Inc. Previously she
spent nine years managing several different Quality departments at
Genentech, Inc. and supported product launches and regulatory
inspections for Genentech's oncology, cardiac and growth hormone
products released during that timeframe. Prior to that, she worked
at Amgen Inc. in Quality Assurance supporting product launches, new
facility preparations for GMP approval, compliance auditing and lot
release for Epogen(R) and Neupogen(R). Before that, Ms. Morandi was
employed by the Clinical Laboratory of Saint Francis Hospital,
Santa Barbara and Ortho Diagnostics. She holds a B.A. degree from
the University of California at Santa Barbara and a M.S. degree in
Immunology from California State University at Northridge. Patricia
Richards, M.D., Ph.D., vice president of clinical research, joined
Corgentech in December 2005 from AlgoRx Pharmaceuticals. Dr.
Richards joined AlgoRx in 2004 where she led the Phase 3 clinical
research program for ALGRX 3268 and the clinical research program
for ALGRX 4975. From 2000 to 2004, Dr. Richards served as medical
director for pain development programs at Purdue Pharma, a
privately held pharmaceutical company. Prior to that, Dr. Richards
was assistant professor of anesthesiology at New York University,
serving as attending physician in the Pain Clinic and in the
operating room, as well as working on clinical research programs
for pain medications. Before that, Dr. Richards was director of the
Pain Management Program at Piedmont and Northside Hospitals which
followed her serving as assistant professor and a pain specialist
at Johns Hopkins Hospital. Dr. Richards obtained a Ph.D. in
pharmacology and an M.D. from the University of Chicago Pritzker
School of Medicine and completed residencies in Internal Medicine
and Anesthesiology and a fellowship in Pain Management at Johns
Hopkins. Jennifer Cook Williams, vice president of investor
relations, joined Corgentech in 2004 and most recently served as
senior director of investor relations. Ms. Williams is responsible
for managing the corporate communications and investor relations
functions at the company. Prior to joining Corgentech, she was with
biotechnology company, Cell Genesys, Inc., for nearly 10 years
where she most recently served as director of corporate
communications and investor relations. Ms. Williams is on the
investor relations advisory committee to the Biotechnology Industry
Organization and has served on the board of the Silicon Valley
Chapter of the National Investor Relations Institute (NIRI) since
2003. She holds a B.S. degree in Finance/Accounting from Central
Washington University. About Corgentech Corgentech is a late-stage
biopharmaceutical company focused on the development and
commercialization of novel therapeutic treatments for pain
management and inflammation. Corgentech is based in South San
Francisco, CA. For more information on the company, please visit
http://www.corgentech.com/. Forward Looking Statements This press
release includes "forward-looking statements" within the meaning of
the safe harbor provisions of the United States Private Securities
Litigation Reform Act of 1995. Words such as "expect," "estimate,"
"project," "budget," "forecast," "anticipate," "intend," "plan,"
"may," "will," "could," "should," "believes," "predicts,"
"potential," "continue," and similar expressions are intended to
identify such forward-looking statements. Forward-looking
statements in this press release include, without limitation,
projected timing of FDA filings and other matters that involve
known and unknown risks, uncertainties and other factors that may
cause actual results, levels of activity, performance or
achievements to differ materially from results expressed or implied
by this press release. Such risk factors include, among others:
whether Corgentech can successfully develop new products and the
degree to which these gain market acceptance. Actual results may
differ materially from those contained in the forward-looking
statements in this press release. Additional information concerning
these and other risk factors is contained in Corgentech's Form S-4
as well as Corgentech's Form 10-K/A for the year ended December 31,
2004 and most recently filed Form 10-Q. Corgentech undertakes no
obligation and does not intend to update these forward-looking
statements to reflect events or circumstances occurring after this
press release. You are cautioned not to place undue reliance on
these forward-looking statements, which speak only as of the date
of this press release. All forward-looking statements are qualified
in their entirety by this cautionary statement. DATASOURCE:
Corgentech Inc. CONTACT: Jennifer Cook Williams, Vice President,
Investor Relations, of Corgentech Inc., +1-650-624-9600, or Web
site: http://www.corgentech.com/
Copyright
Corgentech (NASDAQ:CGTK)
Historical Stock Chart
From Apr 2024 to May 2024
Corgentech (NASDAQ:CGTK)
Historical Stock Chart
From May 2023 to May 2024